- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Fred Hutch Cancer Center | Strategic Alliance Partners
Latest from Fred Hutch Cancer Center
Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer
November 11, 2024
Video
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
November 11, 2024
Video
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer
November 11, 2024
Video
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer
November 11, 2024
Video
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer
November 11, 2024
Video
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management
November 06, 2024
Article
Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.
Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AI
November 05, 2024
Article
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.
Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in Myeloma
October 08, 2024
Video
Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.
Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma
September 24, 2024
Video
Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.
Dr Banerjee on the Benefit of Bispecific Antibody Dose Reduction in Multiple Myeloma
September 16, 2024
Video
Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.
Dr Banerjee on the Impact of Dose Modification Studies in Multiple Myeloma
September 13, 2024
Video
Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.
Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies
September 02, 2024
Article
Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.
Dr Banerjee on Various Dosing Schedules of Bispecific Antibodies in Myeloma
August 29, 2024
Video
Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.
Dr Shadman on the Impact of Early Dose Reduction on Real-World Outcomes With Ibrutinib in CLL/SLL
August 28, 2024
Video
Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.
Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma
August 27, 2024
Article
Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.
Time-Limited Bispecific Antibodies Could Represent Next Shift in Myeloma Treatment
August 26, 2024
Article
Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.
Dr Banerjee on Selecting Between Bispecific and CAR T-Cell Treatments in Myeloma
August 16, 2024
Video
Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma
Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers
August 13, 2024
Video
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC
August 13, 2024
Video
Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.
Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC
August 13, 2024
Video
Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.